Full Press Release Details
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis.
KYTX
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis
Key Takeaway: Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis